Breast cancer, one of the most common cancers among women, could soon benefit from a new therapeutic approach. A new molecule ...

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck ...

Researchers from the University of Sharjah have identified a common herb, Artemisia herba-alba, as a potential natural ...

Long-term TNFi use in patients with psoriasis was not associated with a higher risk of cancer, including lymphoma, prostate cancer, and breast cancer.

Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic ...

Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings ...